TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

1,5200

07-января-25 15:45:00

15 мин. задержка

Акции

+0,1700

+12,59%

Сегодняшний диапазон

1,2500 - 1,5700

ISIN

N/A

Источник

NASDAQ

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian

10 июл 2024 07:05:00 Источник Nasdaq GlobeNewswire
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

08 июл 2024 15:07:16 Источник Nasdaq GlobeNewswire
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

26 июн 2024 11:46:13 Источник Nasdaq GlobeNewswire
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

25 июн 2024 07:05:00 Источник Nasdaq GlobeNewswire
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

18 июн 2024 14:17:05 Источник Nasdaq GlobeNewswire
Tevogen Bio Set to Join Russell 3000® Index

12 июн 2024 14:45:00 Источник Nasdaq GlobeNewswire
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

11 июн 2024 14:30:00 Источник Nasdaq GlobeNewswire
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

07 июн 2024 14:32:04 Источник Nasdaq GlobeNewswire
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

06 июн 2024 17:14:31 Источник Nasdaq GlobeNewswire
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

06 июн 2024 14:52:26 Источник Nasdaq GlobeNewswire
Tevogen Bio Reports First Quarter 2024 Financial Results

29 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

16 май 2024 13:00:00 Источник Nasdaq GlobeNewswire
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

10 май 2024 16:40:49 Источник Nasdaq GlobeNewswire
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

01 май 2024 07:05:00 Источник Nasdaq GlobeNewswire
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

26 апр 2024 08:23:59 Источник Nasdaq GlobeNewswire
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

11 апр 2024 07:05:00 Источник Nasdaq GlobeNewswire
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

03 апр 2024 07:05:00 Источник Nasdaq GlobeNewswire
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

28 мар 2024 07:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.